Trial · NCT05061771
Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
NCT05061771, Phase 3, Withdrawn, AKARI Therapeutics
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP). Trials, record NCT05061771. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05061771
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
- NCT number
- NCT05061771
- Status
- Withdrawn
- Phases
- Phase 3
- Enrollment
- 0 participants, actual
- Lead sponsor
- AKARI Therapeutics
- Conditions
- Bullous Pemphigoid
- Interventions
- nomacopan (rVA576), Placebo
- First posted
- 2021-09-30
- Last updated
- 2025-04-09
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Achievement of Complete Disease Remission | weeks 16 - 24 | Proportion of patients in Complete Disease Remission |
| Secondary | Cumulative oral corticosteroid, OCS, during treatment | Randomization to 24 weeks | Cumulative OCS used during treatment |
| Secondary | Proportion of patients requiring rescue therapy | Randomization to 24 weeks | Proportion of patients requiring rescue therapy during the 24 weeks of treatment |
| Secondary | Achievement Partial Disease Remission | weeks 16 - 24 | Proportion of patients in Partial Disease Remission |
| Secondary | Time to onset of Complete Disease Remission | week 6 to 24 | Time (weeks) to onset of Complete Disease Remission |
| Secondary | Duration of Complete and Partial Disease Remission | week 6 to 24 | Duration (weeks) of Complete Disease Remission and Partial Disease Remission |
| Secondary | Investigator Global Assessment (IGA) score | weeks 6 - 24 | Proportion of patients with Investigator Global Assessment (IGA) score of 0 or 1 |
| Secondary | Adverse Events | Day 1 to Week 28 | Frequency, type and relationship of AEs to treatment |
| Secondary | Steroid-related AEs | Day 1 to Week 28 | Incidence of steroid-related AEs |
| Secondary | Dermatology Life Quality Index (DLQI) | Randomisation to week 24 | Change from baseline in Dermatology Life Quality Index (DLQI) |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05061771
GET https://conductscience.org/api/trials/v1/NCT05061771/registered